Search

Displaying results 2401 - 2410 of 10000 in total
  1. Drug

    Bordetella pertussis fimbriae 2/3 antigen

    go.drugbank.com/drugs/DB10790
    ApprovedInvestigational

    Bordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct

    Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, , Suspension for Injection
  2. Drug

    Streptococcus pneumoniae type 18c capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10335
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 18c capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 18c of *Streptococcus pneumoniae

    Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For Injection
  3. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    [L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is … novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine.

  4. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [L43190] A formulation for subcutaneous use that combines efgartigimod alfa and hyaluronidase was later approved for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP

  5. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    or second-line threapies for treatment-naïve patients as adjunct to sofosbuvir treatment for genotype 1 or PEG-Interferon/ribavirin combination therapy for genotype 1 or 4. … In patients with HCV genotype 1 with compensated cirrhosis, the treatment is directed for 24 week duration.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and

    Synonyms: N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide
  7. Drug

    Futibatinib

    go.drugbank.com/drugs/DB15149
    ApprovedInvestigational

    [L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800] … [A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.

    Synonyms: 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one
  8. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. … It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles.

    Categories: Tests for Bile Duct Patency
  9. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    The non-stimulant norepinephrine/dopamine reuptake inhibitor [DB01156] (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of … Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD).

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  10. Target

    Stromal cell-derived factor 1

    go.drugbank.com/bio_entities/BE0001150
    TargetHumans

    Has several critical functions during embryonic development; required for B-cell lymphopoiesis, myelopoiesis in bone marrow and heart ventricular septum formation (By similarity). … Induces down-regulation and internalization of ACKR3 expressed in various cells.

    Synonyms: Intercrine reduced in hepatomas